Neoleukin Therapeutics Inc

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.

Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference

– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model –  –  Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model –

Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)

SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021).

Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)

SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021) taking place November 10-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C.

Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright 23rd Annual Global Life Sciences Conference taking place September 13-15, 2021.

Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. Eastern Time.

Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference

- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -

Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update

The FDA has removed the clinical hold related to Neoleukin Therapeutics Inc (NASDAQ: NLTX) investigational new drug application, to begin a Phase 1 program of its cancer immunotherapeutic candidate, NL-201. Back in January this year, the FDA asked the company for more information on its de novo IL-5/IL-2 agonist for solid tumors before jumping into human trials.

Ne­oleuk­in's IL-2 Agonist Candidate Cleared To Start Phase 1 Trial In Solid Tumors

Neoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript

- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 -

Neoleukin Therapeutics Announces Year End 2020 Financial Results

SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks | 2021 Oncology Days on Friday, March 12, 2021 at 3 p.m. Eastern Time.

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

Neoleukin is a leader in de novo drug design. The company's lead asset was recently put on clinical hold, pending more dosing data, creating a window to buy the stock.

Neoleukin Therapeutics: De Novo Protein Design Platform

New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su ch investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Neoleukin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX

Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) -  Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal securities laws. On January 8, 2021, Neoleukin announced that "on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201."...

SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC

The company is experiencing regulatory headwinds.

Why Neoleukin Therapeutics Stock Is Down Today

Aquinox (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aquinox (NLTX) Moves to Buy: Rationale Behind the Upgrade

SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.

Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value-add is its specialization in novel-protein design. Neoleukin is developing one clinical therapeutic, NL-201 which is an IND-Phase 1 IL-2/IL-15 immunotherapy being studied for relapsed or refractory solid tumors, a projected $183B market.

Neoleukin: New Phase 1 Initiation, Strong Managerial Expertise, And Promising Technology

SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the submission of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration to begin a Phase 1 clinical program of its lead immunotherapeutic candidate, NL-201. NL-201 is a computationally designed de novo protein that is a mimetic of natural cytokines IL-2 and IL-15.

Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1-3, 2020.

Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference

SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:40 p.m. Eastern Time.

Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation -

Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020)

- NL-201 IND submission anticipated by year end 2020 -

Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update

- I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection –

News for Neoleukin Therapeutics Inc Stock (NLTX)